Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00107016 · ClinicalTrials.gov registry record · Phase 2
Everolimus and Letrozole as Preoperative Therapy of Primary Breast Cancer in Post-menopausal Women
A Phase 2 study of Breast Neoplasm, sponsored by Novartis Pharmaceuticals.
- Completed
- Registry status
- Phase 2
- Development phase
- 267
- Enrollment target
- 20
- Study locations
NCT00107016: Completed Phase 2 study of Breast Neoplasm, sponsored by Novartis Pharmaceuticals.
NCT00107016 is a Phase 2 study of Breast Neoplasm that has completed, run by Novartis Pharmaceuticals. The registered enrollment target is 267 participants, above the 153-participant average among 26 other Breast Neoplasm trials with a reported enrollment target (75% higher). The trial reports 20 study locations across 10 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00107016, a Phase 2 study of Breast Neoplasm, has completed, sponsored by Novartis Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 267 participants
- Enrollment target
- 20
- Study locations
Study Summary
The purpose of this study is to examine the effect of the combination of everolimus and letrozole compared to placebo and letrozole as pre-surgical therapy in patients with newly diagnosed estrogen receptor positive breast cancer.
Conditions Studied
Interventions
- DRUG Letrozole 2.5mg
- DRUG RAD001, Letrozole 2.5mg
Study Locations (20)
Other
- Novartis Investigative Site - Salzburg
- Novartis Investigative Site - Vienna
- Novartis Investigative Site - Wilrijk
- Novartis Investigative Site - Natasha
- Novartis Investigative Site - Winnipeg
- Novartis Investigative Site - Besançon
- Novartis Investigative Site - Bordeaux
- Novartis Investigative Site - Montpellier
- Novartis Investigative Site - Paris
- Novartis Investigative Site - Saint-Herblain
California
- Breastlink Medical Group Inc. - Long Beach
- UCSF Breast Care Center - San Francisco
Arkansas
- Highlands Oncology Group - Springdale
Florida
- University of Miami - Miami
Illinois
- Loyola University Medical Center - Maywood
Indiana
- Investigative Clinical Research of Indiana - Indianapolis
Louisiana
- Ochsner Clinic Foundation - New Orleans
Michigan
- University of Michigan - Ann Arbor
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 267 participants |
| Start Date | 2005-03 |
| Est. Completion | 2007-04 |
| Phase | Phase 2 |
What the finished NCT00107016 record still lists
NCT00107016 is an interventional study that assigns participants to a tested intervention. The registered 267 participants enrollment target is mid-sized for trials with a published cap, above the 153-participant average among 26 other Breast Neoplasm trials with a reported enrollment target (75% higher).
The record links to 1 condition, with Breast Neoplasm appearing as the primary indexed condition, and to 2 interventions - of which Letrozole 2.5mg is the first listed.
NCT00107016 names 20 study sites across 10 states, led by Other, California, Arkansas.
Frequently Asked Questions
What is clinical trial NCT00107016 about?
NCT00107016 is a clinical study titled "Everolimus and Letrozole as Preoperative Therapy of Primary Breast Cancer in Post-menopausal Women". The purpose of this study is to examine the effect of the combination of everolimus and letrozole compared to placebo and letrozole as pre-surgical therapy in patients with newly diagnosed estrogen receptor positive breast cancer.
What is the current status of trial NCT00107016?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 267 participants. The study started on 2005-03. Estimated completion is 2007-04.
What conditions does trial NCT00107016 study?
This clinical trial studies the following conditions: Breast Neoplasm.
What interventions are being tested in trial NCT00107016?
The interventions under investigation include: Letrozole 2.5mg (DRUG), RAD001, Letrozole 2.5mg (DRUG).
Who is sponsoring clinical trial NCT00107016?
This trial is sponsored by Novartis Pharmaceuticals, which has 1,375 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00107016 being conducted?
This trial has 20 study locations across Arkansas, California, Florida, Illinois, Indiana. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Breast Neoplasm
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00107016's enrollment target sits among peer trials
267 6th of 26 higher than 21 of 26 other Breast Neoplasm trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Breast Neoplasm trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Correlation of Clinical Response to Pathologic Response in Patients With Early Breast Cancer
RECRUITING · Phase 2
-
Phase II Protocol of Proton Therapy for Partial Breast Irradiation in Early Stage Breast Cancer
RECRUITING · Phase 2
-
Proton Radiation for Stage II/III Breast Cancer
ACTIVE NOT RECRUITING · Phase 2
-
Comparing Letrozole Given Alone to Letrozole Given With Avastin in Post-Menopausal Women Breast Cancer
COMPLETED · Phase 2
-
Evaluation of a New Agent for Treatment of Advanced Stage Breast Cancer
COMPLETED · Phase 2
-
Surviving Daily Life
RECRUITING
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04997109 · 267 participants · NA
Telemedicine in Early Childhood Constraint Therapy in Cerebral Palsy
- NCT05355701 · 267 participants · Phase 1
A Study to Learn About the Study Medicine Called PF-07799933 in People With Advanced Solid Tumors With BRAF Alterations.
- NCT06203509 · 267 participants · NA
Improving Care Transitions for Medicaid Insured Individuals With Co-occurring Serious Mental Illness
- NCT05000632 · 268 participants · NA
Smoke Free SafeCare: Establishing a Smoke Free Home in CPS-involved Families
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia